Apricoxib

Drug Profile

Apricoxib

Alternative Names: Capoxigem; CS-706; Kymena; R-109339; TG 01; TP1001 programme; TP2001 programme

Latest Information Update: 06 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Tragara Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Inflammation; Inflammatory pain; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 09 Jul 2015 Tragara Pharmaceuticals completes a phase II trial in Non-small cell lung cancer (Combination therapy, late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (NCT00771953)
  • 07 Jun 2011 Final efficacy data from the phase II APRiCOT-L trial in recurrent late-stage or metastatic Non-small cell lung cancer (second-line therapy, in combination with erlotinib) presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO-2011)
  • 26 May 2011 Pharmacodynamics data from animal studies in solid tumours released by Tragara Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top